How durable are the responses of CLL patients to therapy?
Venetoclax and ibrutinib and drug combinations for CLL
Side effects of idelalisib in CLL and how to manage them
ROR1 and its role in CLL and other cancers
PEP-C for treatment of relapsed/refractory lymphoma